梶波 康二 かじなみ こうじ 先生

来歴等

略歴

1984年 金沢大学医学部 卒業
1988年 金沢大学大学院医学系研究科 修了　医学博士取得
1994年 金沢大学医学部第二内科 助手
1999年 金沢大学医学部附属病院第二内科 講師
1999年 金沢医科大学循環器内科学 講師
2001年 金沢医科大学循環器内科学 助教授
2002年 Tufts大学（米国マサチューセッツ州ボストン） 留学
2004年 金沢医科大学循環器内科学 主任教授

論文

• New variant of low density lipoprotein receptor gene. FH-Tonami. Arteriosclerosis 8:187- 192,1988.

  Kajinami K, Mabuchi H, Itoh H, Michishita I, Takeda M, Wakasugi T, Koizumi J, Takeda R

• Novel gene mutations at the low density lipoprotein receptor locus. FH-Kanazawa and FH-Okayama. J Intern Med 227:247-251,1990.

  Kajinami K, Mabuchi H, Inazu A, Fujita H, Koizumi J, Takeda R, Matsue T, Kibata M

• Asymptomatic congenital subclavian steal in a young male patient with right aortic arch. Chest 97:481-482,1990.

  Kajinami K, Mori K, Masuda S, Itoh Y, Morishita E, Imahori E

• Serum apolipoproteins in heterozygous familial hypercholesterolemia Clin Chim Acta 211:93-99,1992.

  Kajinami K, Mabuchi H, Koizumi J, Takeda R

• Propranolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia. Lancet 341:124-125,1993.

  Kajinami K, Takekoshi N, Mabuchi H

• Internal mammary-to-coronary artery communication in a patient with occluded right coronary artery. Am Heart J 125:1428-1430,1993.

  Kajinami K, Takekoshi N, Yoshio H

• Quantification of coronary artery calcification using ultrafast computed tomography: reproducibility of measurements. Coron Artery Dis 4:1103- 1108,1993.

  Kajinami K, Seki H, Takekoshi N, Mabuchi H

• Omeprazole and diminished antianginal drug delivery. Ann Intern Med 121:385-386,1994.

  Kajinami K, Mabuchi H

• Noninvasive prediction of coronary atherosclerosis by quantification of coronary artery calcification using electron beam computed tomography: comparison with electrocardiographic and thallium exercise stress test results. J Am Coll Cardiol 26:1209-1221,1995.

  Kajinami K, Seki H, Takekoshi N, Mabuchi H

• Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolemia. Lancet 345:1438,1995.

  Nohara A, Yagi K, Inazu A, Kajinami K, Koizumi J, Mabuchi H

• Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heteozygous patient with familial hypercholesterolemia. Atherosclerosis 120:181-187,1996.

  Kajinami K, Nishitsuji M, Takeda Y, Shimizu M, Koizumi J, Mabuchi H

• Coronary calcification and coronary atherosclerosis: site by site comparative morphologic study of electron beam computed tomography and coronary angiography. J Am Coll Cardiol 29:1549-1556,1997.

  Kajinami K, Seki H, Takekoshi N, Mabuchi H

• Non-invasive detection of quadricuspid aortic valve. Heart 78:87,1997.

  Kajinami K, Takekoshi N, Mabuchi H

• Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am J Cardiol 82:113-117,1998.

  Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H

• Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipidol 10:401-406,1999.

  Kajinami K, Mabuchi H

• Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinases. Modern Pathol 12:1174-1180,1999.

  Kajinami K, Kasashima S, Oda Y, Shimizu M, Koizumi J, Katsuda S, Mabuchi H

• Effects of NK-104, a new hydroxy-methylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol 85:178-183,2000.

  Kajinami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, Mabuchi H, the Hokuriku NK-104 Study Group

• NK-104: a novel synthetic HMG-CoA reductase.Exp Opin Invest Drugs 9:2653-2661,2000.

  Kajinami K, Mabuchi H, Saito Y.

• Pitavastatin: efficacy and safety profile of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 21:199-215,2003.

  Kajinami K, Takekoshi N, Saito Y

• Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 92:1113-1116,2003.

  Kajinami K, Takekoshi N, Matsui S, Kanemitsu S, Okubo S, Kanayama S, Yamashita N, Sato R

• CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93:104-107,2004.

  Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ

• ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 45:653-656,2004.

  Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ

• Polymorphisms in the multidrug resistance 1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93:1046-1050,2004.

  Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ

• Imbalance of sex hormone levels in men with coronary artery disease. Coronary Artery Disease15;199-203,2004.

  Kajinami K,Takeda K, Takekoshi N, Matsui S, Tsugawa H, Kanemitsu S, Okubo S, Kitayama M, Fukuda A

• Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 175:287-293,2004.

  Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ

• Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177:219-234,2004.

  Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ

• Gender-specific effects of estrogen receptor α gene haplotype on lipid response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 178:331-338,2005.

  Kajinami K, Brousseau ME, Lamon-Fava S, Ordovas JM, Schaefer EJ

• A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 180:407-415,2005.

  Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ

• Statin response and pharmacokinetics variants. Exp Opin Pharmacother 6:1291-1297,2005.

  Kajinami K, Masuya H, Hoshiba Y, Takeda K, Sato R, Okabayashi M, Schaefer EJ

• Pharmacogenomics of statin responsiveness. Am J Cardiol 96[suppl]:65K-70K,2005.

  Kajinami K, Akao H, Polisecki E, Schaefer EJ

• Statin pharmacogenomics: what have we learned, and what remains unanswered? Curr Opin Lipidol 16:606-613,2005.

  Kajinami K, Okabayashi M, Sato R, Polisecki E, Schaefer EJ

• Quantitation of cardiac sympathetic innervation in rabbits using (11)C-hydroxyephedrine PET: relation to (123)I-MIBG uptake. Eur J Nucl Med Mol Imaging. 33:871-878,2006.

  Nomura Y, Matsunari I, Takamatsu H, Murakami Y, Matsuya T, Taki J, Nakajima K, Nekolla SG, Chen WP, Kajinami K

• Beyond C-reactive protein: new evidence for another inflammatory biomarker predicting cardiovascular disease risk. Atherosclerosis 214:39-40,2011.

  Kajinami K, Kawai Y

• Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther 5:283-297,2011.

  Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K

• Probucol: Can we step forward in atherosclerosis prevention with an old drug? Atherosclerosis 2012 Mar;221(1):34-5

  Kajinami K, Akao H

• Serum deoxyribonuclease I activity can be a useful diagnostic marker for the early diagnosis of unstable angina pectoris or non-ST-segment elevation myocardial infarction. J Cardiol. 2012;59:258-265.

  Fujibayashi K, Kawai Y, Kitayama M, Akao H, Ishida R, Motoyama A, Wakasa M, Arakawa K, Ueki M, Kajinami K, Yasuda T

• Myocardial sympathetic innervation, function, and oxidative metabolism in non-infarcted myocardium in patients with prior myocardial infarction. Ann Nucl Med. 2013;27:523-531.

  Aoki H, Matsunari I, Nomura Y, Fujita W, Komatsu R, Miyazaki Y, Nekolla SG, Kajinami K

• Chk1-mediated phosphorylation of receptor-associated late transducer at serine 250 increases its stability by stimulating its interaction with 14-3-3. Genes Cells. 2013 May;18(5):369-86.

  Takeda K, Takata T, Kawai Y, Ishigaki Y, Kajinami K

• Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake. J Thromb Thrombolysis. 2014;38:105-114.

  Saito R, Takeda K, Yamamoto K, Nakagawa A, Aoki H, Fujibayashi K, Wakasa M, Motoyama A, Iwadare M, Ishida R, Fujioka N, Tsuchiya T, Akao H, Kawai Y, Kitayama M, Kajinami K

• Increased levels of the oxidative stress marker, nitrotyrosine in patients with provocation test-induced coronary vasospasm. J Cardiol. 2014 Aug;64(2):86-90.

  Tanabe K, Kawai Y, Kitayama M, Akao H, Ishida R, Motoyama A, Wakasa M, Saito R, Aoki H, Fujibayashi K, Watanabe M, Tsuchiya T, Kimura H, Yoshida K, Kajinami K

• ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis 2014;235:176-181.

  Akao H, Polisecki1 E, Schaefer EJ, Trompet S, Robertson M, Ford I, Jukema JW, de Craen AJM, Packard C, Buckley BM, Kajinami K

• Circulating glutamate and taurine levels are associated with the generation of reactive oxygen species in paroxysmal atrial fibrillation. Disease Markers 2016;2016:7650976.

  Takano S, Fujibayashi K, Fujioka N, Ueno E, Wakasa M, Kawai Y, Kajinami K

• Lipoprotein(a): revisiting a next therapeutic target. Circ J 2016;80:329-331.

  Kajinami K

• Prediction of all-cause death using 11C hydroxyephedrine positron emission tomography in Japanese patients with left ventricular dysfunction. Ann Nucl Med. 2016;30:461-467.

  Fujita W, Matsunari I, Aoki H, Nekolla SG, Kajinami K

• Diurnal glycemic fluctuation is associated with severity of coronary artery disease in prediabetic patients: Possible role of nitrotyrosine and glyceraldehyde-derived advanced glycation end products. J Cardiol. 2017 Apr;69(4):625-631.

  Watanabe M, Kawai Y, Kitayama M, Akao H, Motoyama A, Wakasa M, Saito R, Aoki H, Fujibayashi K, Tsuchiya T, Nakanishi H, Saito K, Takeuchi M, Kajinami K

• Possiible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metabolism and Pharmacokinetics　2016;31:467-470.

  Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, Takeda K, Tanimoto T, Yamano T, Akasaka T, Ishida T, Hirata K, Saku K, Yagi S, Soeki T, Sata M, Ueno M, Miyazaki S, Shiraki A, Oyama J, Node K, Sugamura K, Ogawa H, Kurose K, Maekawa K, Matsuzawa Y, Imatoh T, Hasegawa R, Japanese Pharmacogenomics Data Science Consortium, Saito Y

• Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD). Atherosclerosis, 2017;263:192-197.

  Takamura T, Tsuchiya T, Oda M, Watanabe M, Saito R, Sato-Ishida R, Akao H, Kawai Y, Kitayama M, Kajinami K

• Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J. 2018;82(4)1008-1016.

  Nagar S, Rane P, Fox K, Meyers J, Davis K, Beaubrun A, Inomata H, Qian Y, Kajinami K

• Toward effective cost-effectiveness analysis in atherosclerotic cardiovascular disease prevention. Circ J. 2018;82(4)954-955.

  Kajinami K

• Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018 Oct 4;379(14):1332-1342.

  Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators

• Real-world data to identify hypercholesterolemia patients on suboptimal statin therapy. J Atheroscler Thromb. 2019 May 1;26(5):408-431.

  Kajinami K, Ozaki A, Tajima Y, Yamashita S, Arai H, Teramoto T

• Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb. 2019 [Epub ahead of print]

  Kajinami K, Tsukamoto K, Koba S, Inoue I, Yamakawa M, Suzuki S, Hamano T, Saito H, Saito Y, Masuda S, Nakayama T, Okamura T, Yamashita S, Kagawa T, Kaneyama J, Kuriyama A, Tanaka R, Hirata A: Statin Intolerance Clinical Guide Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics

• Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metab Pharmacokinet. 2019;34:387-396.

  Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y

• Evolocumab vs. ezetimibe in statin-intolerant hyperlipidemic Japanese patients: phase 3 GAUSS-4 trial. J Atheroscler Thromb (in press).

  Koba S, Inoue I, Cyrille M, Lu C, Inomata H, Shimauchi J, Kajinami K

著書

• 【共著】岩垂瑞穂、梶波康二．　家族性複合型高脂血症．　寺本民生編　コレステロール　基礎か ら臨床へ　ライフサイエンス出版社　p136-140, 2009年

• 【共著】梶波康二．　アテローム硬化性動脈瘤 (p41)，アテローム症 (p41)，アテローム性動脈硬化 症 (p42)，異常βリポ蛋白血症 (p122)， LDL受容体関連蛋白 (p290)，脂肪心 (p1233)，粥腫 崩壊 (p1271)，粥状硬化性壊疽 (p1271)，前粥状硬化病変(p1621)，増殖性細動脈硬化 (p1679)，動脈硬化性高血圧症 (p2004)，動脈硬化性心血管疾患 (p2004)，動脈壁の硬化度 (p2005)，軟性粥腫 (p2079)，非アテローム性動脈硬化性動脈瘤 (p2296)．　伊藤正男・井村 裕夫・高久史麿総編集　医学大辞典　　医学書院　2009年

• 【共著】梶波康二、高野信太郎、高村敬明．　冠動脈疾患予防に対する脂質異常症の治療 (ACC/AHAガイドライン2013と新しい治療展望)　小室一成・佐地　勉・坂田隆造・赤阪隆 史編　Annual Review 2015循環器　中外医学社　p86-92 　2015年

• 【共著】岩垂瑞穂、梶波康二．　脂質異常症（高脂血症）．永井良三・伊藤　浩編　循環器疾患最 新の治療2016-2017　南江堂　p491-495　2016年

• 【共著】梶波康二、斉藤竜平．循環器領域における血栓性疾患の治療．　朝倉英策編　臨床に直結 する血栓止血学　改訂第２版　中外医学社　p474-478．2018年

• 【共著】梶波康二、佐伯泰彦．　スタチン不耐．　山下静也編　別冊・医学のあゆみ　動脈硬化 UPDATE　医歯薬出版　p142-146, 2019年

特許

• 竹田健史、梶波康二．　生細胞中での組み換え蛋白質を迅速に分解する方法． 特願2015-216258．出願日：平成27年11月4日 特開2017-85911．公開日：平成29年5月25日

その他

• 【受賞】第４回日本内科学会奨励賞（1991年4月） 遺伝子レベルで規定された軽症家族性高コレステロール血症：FH-Tonami-2